Inventor · disambiguated record
Timothy Kogan
Also filed as: KOGAN TIMOTHY · KOGAN TIMOTHY P
35 granted patents·1 pending application·1,275 citations·filing 1986–2003
98Inventor score
Files withTEXAS BIOTECHNOLOGY CORP19GENENTECH INC8SCHERING CORP5ENCYSIVE PHARMACEUTICALS INC2TEXAS BIOTECHNOLOGY CORP INC1
Top patents by PatentIndex Score
36 records- 0194US5329028ACarbohydrate-directed cross-linking reagentsGENENTECH INC·Filed 1992·Granted Jul 12, 1994·87 cites·13 claims
- 0294US5250732AKetamine analogues for treatment of thrombocytopeniaGENENTECH INC·Filed 1991·Granted Oct 5, 1993·60 cites·5 claims
- 0393US5384331AKetamine analogues for treatment of thrombocytopeniaGENENTECH INC·Filed 1993·Granted Jan 24, 1995·43 cites·4 claims
- 0492US5962490AThienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1996·Granted Oct 5, 1999·93 cites·97 claims
- 0592US5510332AProcess to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides thereforTEXAS BIOTECHNOLOGY CORP·Filed 1994·Granted Apr 23, 1996·151 cites·15 claims
- 0691US6582928B1Carbohydrate-directed cross-linking reagentsGENENTECH INC·Filed 2000·Granted Jun 24, 2003·16 cites·17 claims
- 0790US5889155ACarbohydrate-directed cross-linking reagentsGENENTECH INC·Filed 1995·Granted Mar 30, 1999·83 cites·18 claims
- 0889US5444050ABinding of E-selectin or P-selectin to sialyl Lewisx or sialyl-LewisaTEXAS BIOTECHNOLOGY CORP·Filed 1994·Granted Aug 22, 1995·93 cites·19 claims
- 0988US6458805B2Formulation of sulfonamides for treatment of endothelin-mediated disordersTEXAS BIOTECHNOLOGY CORP·Filed 2001·Granted Oct 1, 2002·30 cites·65 claims
- 1087US6683103B2Sulfonamides for treatment of endothelin-mediated disordersENCYSIVE PHARMACEUTICALS INC·Filed 2001·Granted Jan 27, 2004·26 cites·44 claims
- 1182US5783705AProcess of preparing alkali metal salys of hydrophobic sulfonamidesTEXAS BIOTECHNOLOGY CORP·Filed 1997·Granted Jul 21, 1998·48 cites·11 claims
- 1281US6248767B1Formulation of sulfonamides for treatment of endothelin-mediated disordersTEXAS BIOTECHNOLOGY CORP·Filed 1997·Granted Jun 19, 2001·46 cites·66 claims
- 1381US6194448B1N, N-disubstituted amides that inhibit the binding of integrins to their receptorsTEXAS BIOTECHNOLOGY CORP·Filed 1999·Granted Feb 27, 2001·42 cites·17 claims
- 1480US5124337AN-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferaseSCHERING CORP·Filed 1991·Granted Jun 23, 1992·41 cites·16 claims
- 1578US6632829B2Sulfonamides and derivatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 2001·Granted Oct 14, 2003·9 cites·55 claims
- 1678US6420567B1N-heteroaryl aryl-substituted thienyl-furyl-and pyrrolyl-sulfonamides and derviatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1997·Granted Jul 16, 2002·32 cites·73 claims
- 1778US5919768ADi- and trivalent small molecule selectin inhibitorsTEXAS BIOTECHNOLOGY CORP·Filed 1996·Granted Jul 6, 1999·61 cites·9 claims
- 1877US6432994B1Sulfonamides for treatment of endothelin-mediated disordersTEXAS BIOTECHNOLOGY CORP·Filed 1998·Granted Aug 13, 2002·30 cites·18 claims
- 1977US5622937ACompositions and methods of inhibiting the binding of E-selectin or P-selectin or sialyl-Lewisx or sialyl-LewisaTEXAS BIOTECHNOLOGY CORP·Filed 1996·Granted Apr 22, 1997·56 cites·6 claims
- 2075US6331637B1N-Alkyl, N-Alkenyl, N-Alkynyl, N-Aryl and N-fused bicyclo or tricyclo thienyl-, furyl-,and Pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1999·Granted Dec 18, 2001·26 cites·60 claims
- 2175US6087330AProcess to inhibit binding of the integrin α4 β1 to VCAM-1 or fibronectin and cyclic peptides thereforTEXAS BIOTECHNOLOGY CORP·Filed 1998·Granted Jul 11, 2000·33 cites·17 claims
- 2275US5149709AInhibitors of acyl-coenzyme A: cholesterol acyl transferaseSCHERING CORP·Filed 1990·Granted Sep 22, 1992·11 cites·16 claims
- 2374US6096773ACompounds that inhibit the binding of integrins to their receptorsTEXAS BIOTECHNOLOGY CORP INC·Filed 1999·Granted Aug 1, 2000·33 cites·10 claims
- 2473US6342610B2N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelinTEXAS BIOTECHNOLOGY CORP·Filed 1996·Granted Jan 29, 2002·18 cites·52 claims
- 2573US6124435ACarbohydrate-directed cross-linking reagentsGENENTECH INC·Filed 1998·Granted Sep 26, 2000·10 cites·22 claims
- 2672US6613804B2Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelinENCYSIVE PHARMACEUTICALS INC·Filed 2001·Granted Sep 2, 2003·5 cites·14 claims
- 2766US6262084B1Compounds that inhibit the binding of integrins to their receptorsTEXAS BIOTECHNOLOGY CORP·Filed 1999·Granted Jul 17, 2001·18 cites·10 claims
- 2866US5238935AN-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme A: cholesterol acyl transferaseSCHERING CORP·Filed 1992·Granted Aug 24, 1993·9 cites·1 claims
- 2959US5605791ACarbohydrate-directed cross-linking reagentsGENENTECH INC·Filed 1995·Granted Feb 25, 1997·6 cites·9 claims
- 3058US5776907AMitomycin oligonucleotide conjugatesTEXAS BIOTECHNOLOGY CORP·Filed 1996·Granted Jul 7, 1998·21 cites·16 claims
- 3155US2003208084A1Sulfonamides and derivatives thereof that modulate the activity of endothelinFiled 2003·Application pending·0 cites
- 3254US5929211ACarbohydrate-directed cross-linking reagentsGENENTECH INC·Filed 1997·Granted Jul 27, 1999·11 cites·17 claims
- 3354US5712387AHigh yield stereospecific mannosylationTEXAS BIOTECHNOLOGY CORP·Filed 1996·Granted Jan 27, 1998·8 cites·4 claims
- 3450US5326762AInhibitors of acyl-coenzyme A: cholesterol acyl transferaseSCHERING CORP·Filed 1992·Granted Jul 5, 1994·3 cites·10 claims
- 3549US6713604B1Process to inhibit binding of the integrin α4β1 , to VCAM-1 fibronectin and cyclic peptides thereofTEXAS BIOTECHNOLOGY CORP·Filed 1996·Granted Mar 30, 2004·7 cites·4 claims
- 3638US4766109AHydrophobic peptidesSCHERING CORP·Filed 1986·Granted Aug 23, 1988·9 cites·16 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →